FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285207416> ?p ?o ?g. }

• W4285207416 endingPage "388" @default.
• W4285207416 startingPage "388" @default.
• W4285207416 abstract "Research on dermatological diseases is limited by the availability of rigorous models that can recapitulate the complexity of native skin. Murine models that are currently employed to study dynamics of skin development and homeostasis fail to mimic human biology, and the available human skin equivalent systems are limited by the absence of hair follicles, dermal fat cells, and sensory neurons.[1] Currently, the management of local and full-thickness skin defects using stem cell therapy stays a considerable clinical challenge due to inefficient skin regeneration protocols. The immense need for refined models of human skin for research as well as diagnostic purposes has encouraged the development of in vitro skin stem cell regeneration models and organoids that can serve as a source of cells for skin reconstruction and propel studies of human skin development, disease modeling, drug testing, and cell/gene therapies. Skin organoids are the most valuable tools to investigate the developmental biology of skin and cross-talk between broad skin cells including the immune and non-immune sub-populations.[2] With the advancement in genetics, imaging, and high-throughput technologies, there has been a progressive trend towards understanding the relationship between resident skin stem cells and their interaction with the immediate niche, which maintains the overall health and integrity of the skin. Any pathological insult, if not rescued by the adult stem cell populations of the skin, can result in dermatological diseases that can involve/affect diverse skin cells including the ectodermal derivatives (epidermis), mesenchymal derivatives (dermis, hypodermis, and mesodermal connective tissue), resident immune and vascular cells, sensory nerve endings, and neural crest-derived Schwann cells and melanocytes. The establishment of novel platforms involving the generation of superior neuro-vascularized skin organoids marked by co-development of pericytes, endothelial cells, neurons, melanocytes, Schwann cells, and hematopoietic stem cells or immune cells could facilitate the investigation of infectious inflammatory skin diseases such as erythema nodosum leprosum (ENL)/type 2 leprosy reactions (T2R). Further, patient-derived skin organoids could offer room for understanding patient heterogeneity that may allow for personalized therapies for the treatment of diverse skin diseases. Improved skin organoids, therefore, hold great potential to feed-forward exploratory research toward investigating complex nerve sensation and microbiome-skin interactions, dermatological viral–bacterial co-infections, and high-throughput drug screening, thereby massively advancing basic and clinical research. The recent work by Lee et al.[3] has demonstrated methods to generate skin organoid models from pluripotent stem cells.[4] More than 150 years after being identified as a human pathogen, Mycobacterium leprae has defied ex-vivo cultivation. Numerous attempts have been made to cultivate the bacteria ex-vivo on axenic culture media as well as in cell culture; however, fastidious growth requirements have led to repeated failure in culture attempts. This had posed major limitations to gaining deeper mechanistic insights into the pathophysiology of leprosy, especially leprosy reactions including ENL. Animal models including long-nosed southern nine-banded armadillo (Dasypus novemcinctus) and mouse footpad (Mus musculus) models- the “gold standard animal model” for leprosy research as well as in vitro (human and mouse) leprosy granuloma models involving M. leprae “infection” have been discovered and established over time. None of these models display the full clinical manifestations of the leprosy spectrum including nerve infection and type 1/type 2 leprosy reactions that are seen in humans. This has been a critical deterrent for investigative research into these serious life-threatening phenomena associated with long-term incapacitation seen in humans. There is a critical need for validated in vitro models of leprosy reactions to use as an exploratory research tool for investigating molecular and cellular players underlying ENL-associated multi-system inflammation. It is intriguing to leverage this skin organoid model towards the establishment of the novel in vitro M. leprae infected human skin organoids-leprosy granuloma model for studying leprosy, especially reactions. In vitro models consisting of novel vascularized and innervated (Schwann cell myelinated) skin organoids infected with M. leprae and co-cultured with autologous peripheral immune cells can help elucidate the pathophysiology of granuloma formation and immune reshaping underlying ENL.[5] Building and establishing holistic skin organoids by coaxing ectodermal patterning into epidermal and non-epidermal co-emerging lineage derivative, neural crest cells that have the potential to give rise to mesenchymal derivatives (dermis), and Schwann cells (the preferred incubating sites of M. leprae) seems quite promising. A successful infection, survival, and (propagation?) can have path-breaking implications in establishing tractable in vitro personalized ENL models that may help understand the pathophysiology of the disease, develop personalized therapy, and facilitate overcoming the inherent roadblocks and limitations in current leprosy therapeutics. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest." @default.
• W4285207416 created "2022-07-14" @default.
• W4285207416 creator A5022352848 @default.
• W4285207416 creator A5029636462 @default.
• W4285207416 creator A5081503655 @default.
• W4285207416 date "2022-01-01" @default.
• W4285207416 modified "2023-10-17" @default.
• W4285207416 title "”Neuro-Vascularized skin organoids”: Novel exploratory research tools in leprosy" @default.
• W4285207416 cites W2780586384 @default.
• W4285207416 cites W3032142305 @default.
• W4285207416 cites W3097156178 @default.
• W4285207416 cites W3120633623 @default.
• W4285207416 cites W3124575106 @default.
• W4285207416 doi "https://doi.org/10.4103/idoj.idoj_710_21" @default.
• W4285207416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36225996" @default.
• W4285207416 hasPublicationYear "2022" @default.
• W4285207416 type Work @default.
• W4285207416 citedByCount "0" @default.
• W4285207416 crossrefType "journal-article" @default.
• W4285207416 hasAuthorship W4285207416A5022352848 @default.
• W4285207416 hasAuthorship W4285207416A5029636462 @default.
• W4285207416 hasAuthorship W4285207416A5081503655 @default.
• W4285207416 hasBestOaLocation W42852074161 @default.
• W4285207416 hasConcept C105702510 @default.
• W4285207416 hasConcept C10854531 @default.
• W4285207416 hasConcept C142724271 @default.
• W4285207416 hasConcept C169760540 @default.
• W4285207416 hasConcept C171056886 @default.
• W4285207416 hasConcept C198826908 @default.
• W4285207416 hasConcept C203014093 @default.
• W4285207416 hasConcept C2775934546 @default.
• W4285207416 hasConcept C2776391296 @default.
• W4285207416 hasConcept C2776458125 @default.
• W4285207416 hasConcept C2777074287 @default.
• W4285207416 hasConcept C2777459323 @default.
• W4285207416 hasConcept C2777624698 @default.
• W4285207416 hasConcept C2780439664 @default.
• W4285207416 hasConcept C28328180 @default.
• W4285207416 hasConcept C31695470 @default.
• W4285207416 hasConcept C54355233 @default.
• W4285207416 hasConcept C71924100 @default.
• W4285207416 hasConcept C81885089 @default.
• W4285207416 hasConcept C86803240 @default.
• W4285207416 hasConcept C8891405 @default.
• W4285207416 hasConcept C95444343 @default.
• W4285207416 hasConceptScore W4285207416C105702510 @default.
• W4285207416 hasConceptScore W4285207416C10854531 @default.
• W4285207416 hasConceptScore W4285207416C142724271 @default.
• W4285207416 hasConceptScore W4285207416C169760540 @default.
• W4285207416 hasConceptScore W4285207416C171056886 @default.
• W4285207416 hasConceptScore W4285207416C198826908 @default.
• W4285207416 hasConceptScore W4285207416C203014093 @default.
• W4285207416 hasConceptScore W4285207416C2775934546 @default.
• W4285207416 hasConceptScore W4285207416C2776391296 @default.
• W4285207416 hasConceptScore W4285207416C2776458125 @default.
• W4285207416 hasConceptScore W4285207416C2777074287 @default.
• W4285207416 hasConceptScore W4285207416C2777459323 @default.
• W4285207416 hasConceptScore W4285207416C2777624698 @default.
• W4285207416 hasConceptScore W4285207416C2780439664 @default.
• W4285207416 hasConceptScore W4285207416C28328180 @default.
• W4285207416 hasConceptScore W4285207416C31695470 @default.
• W4285207416 hasConceptScore W4285207416C54355233 @default.
• W4285207416 hasConceptScore W4285207416C71924100 @default.
• W4285207416 hasConceptScore W4285207416C81885089 @default.
• W4285207416 hasConceptScore W4285207416C86803240 @default.
• W4285207416 hasConceptScore W4285207416C8891405 @default.
• W4285207416 hasConceptScore W4285207416C95444343 @default.
• W4285207416 hasIssue "3" @default.
• W4285207416 hasLocation W42852074161 @default.
• W4285207416 hasLocation W42852074162 @default.
• W4285207416 hasLocation W42852074163 @default.
• W4285207416 hasLocation W42852074164 @default.
• W4285207416 hasOpenAccess W4285207416 @default.
• W4285207416 hasPrimaryLocation W42852074161 @default.
• W4285207416 hasRelatedWork W1016894628 @default.
• W4285207416 hasRelatedWork W150990555 @default.
• W4285207416 hasRelatedWork W1767931805 @default.
• W4285207416 hasRelatedWork W1977873893 @default.
• W4285207416 hasRelatedWork W2348952358 @default.
• W4285207416 hasRelatedWork W2898563552 @default.
• W4285207416 hasRelatedWork W3156103223 @default.
• W4285207416 hasRelatedWork W4386045749 @default.
• W4285207416 hasRelatedWork W4386258787 @default.
• W4285207416 hasRelatedWork W193816056 @default.
• W4285207416 hasVolume "13" @default.
• W4285207416 isParatext "false" @default.
• W4285207416 isRetracted "false" @default.
• W4285207416 workType "article" @default.